Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 8/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ADK | P55263 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067658 | 0.94 | FLT1 (0.61) | FLT1IKBKBEGFRLMNAMAPK1 | |
| SCHEMBL4071814 | 0.86 | FLT1 (0.55) | FLT1IKBKBEGFRLMNAMAPK1 | |
| SCHEMBL4072529 | 0.86 | TYK2 (0.60) | FLT1IKBKBEGFRLMNAMAPK1 | |
| SCHEMBL4069671 | 0.84 | NPR1 (0.54) | FLT1IKBKBEGFRLMNAMAPK1 | |
| SCHEMBL3930448 | 0.82 | FLT1 (0.56) | FLT1IKBKBEGFRLMNAMAPK1 | |
| SCHEMBL4066934 | 0.81 | CA1 (0.54) | FLT1IKBKBEGFRLMNAKDM4E | |
| SCHEMBL3930470 | 0.81 | FLT1 (0.52) | FLT1IKBKBEGFRLMNAMAPK1 | |
| SCHEMBL3936767 | 0.79 | NPR1 (0.61) | FLT1IKBKBEGFRLMNAMAPK1 | |
| SCHEMBL4072402 | 0.79 | HTT (0.48) | FLT1IKBKBEGFRLMNAMAPK1 | |
| SCHEMBL13242725 | 0.79 | AURKA (0.59) | FLT1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | claimed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | claimed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | FLT1 3521/4885PIK3CD 2103/4885PIK3R1 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.